

Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Dated: August 2, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-19413 Filed 8-4-95; 8:45 am]

BILLING CODE 4140-01-M

Ad Hoc Review Committee for the Recombinant DNA Advisory Committee; Meeting

Notice is hereby given of a meeting of the Ad Hoc Review Committee for the Recombinant DNA Advisory Committee on August 28, 1995, at the National Institutes of Health, Building 31C, 6th Floor, Conference Room 8, 9000 Rockville Pike, Bethesda, Maryland 20892, starting at approximately 9 a.m. to adjournment at approximately 5 p.m. The meeting will be open to the public to discuss three major topics for review: (1) Domain and mandate of the Recombinant DNA Advisory Committee; (2) composition of the Recombinant DNA Advisory Committee; and (3) Recombinant DNA Advisory Committee's review of human gene transfer protocols. Attendance by the public will be limited to space available. Members of the public wishing to speak at this meeting may be given such opportunity at the discretion of the Chair.

Dr. Nelson A. Wivel, Director, Office of Recombinant DNA Activities, Suite 323, National Institutes of Health, 6006 Executive Boulevard, MSC 7052, Bethesda, Maryland 20892-7052, Phone (301) 496-9838, FAX (301) 496-9839, will provide materials to be discussed at this meeting, roster of committee members, and substantive program information. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Wivel in advance of the meeting. A summary of the meeting will be available at a later date.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its

announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers not only virtually every NIH program but also essentially every Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Dated: July 28, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, National Institutes of Health.

[FR Doc. 95-19415 Filed 8-4-95; 8:45 am]

BILLING CODE 4140-01-M

National Institutes of Health Division of Research Grants; Closed Meetings:

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: August 15, 1995.

Time: 8 a.m.

Place: American Inn of Bethesda.

Contact Person: Dr. Joe Marwah, Scientific Review Administrator, 6701 Rockledge Drive, Room 45188, Bethesda, MD 20892, (301) 435-1253.

Name of SEP: Clinical Sciences.

Date: August 18, 1995.

Time: 1 p.m.

Place: NIH, Rockledge II, Room 4218, Telephone Conference.

Contact Person: Dr. Shirley A. Hilden, Scientific Review Administrator, 6701 Rockledge Drive, Room 4218, Bethesda, MD 20892, (301) 435-1198.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 15, 1995.

Time: 10:30 a.m.

Place: NIH, Rockledge II, Room 4182, Telephone Conference.

Contact Person: Dr. William Branche, Scientific Review Administrator, 6701

Rockledge Drive, Room 4182, Bethesda, MD 20892, (301) 435-1148.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 17, 1995.

Time: 10:00 a.m.

Place: NIH, Rockledge II, Room 4182, Telephone Conference.

Contact Person: Dr. William Branche, Scientific Review Administrator, 6701 Rockledge Drive, Room 4182, Bethesda, MD 20892, (301) 435-1148.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 18, 1995.

Time: 10:30 a.m.

Place: NIH, Rockledge II, Room 4182, Telephone Conference.

Contact Person: Dr. William Branche, Scientific Review Administrator, 6701 Rockledge Drive, Room 4182, Bethesda, MD 20892, (301) 435-1148.

Name of SEP: Microbiological and Immunological Sciences.

Date: August 17, 1995.

Time: 1 p.m.

Place: NIH, Rockledge II, Room 4200, Telephone Conference.

Contact Person: Dr. Gilbert Meier, Scientific Review Administrator, 6701 Rockledge Drive, Room 4200, Bethesda, MD 20892, (301) 435-1219.

Name of SEP: Multidisciplinary Sciences.

Date: September 18, 1995.

Time: 8:30 a.m.

Place: Washington Dulles Airport Marriott, VA.

Contact Person: Dr. Harish Chopra, Scientific Review Administrator, 6701 Rockledge Drive, Room 5122, Bethesda, MD 20892, (301) 435-1169.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meetings due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393, 93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 31, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-19414 Filed 8-4-95; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Biological and Physiological Sciences.

Date: August 16, 1995.

Time: 1 p.m.

Place: NIH, Rockledge II, Room 6152, Telephone Conference.

Contact Person: Dr. Jerry Roberts, Scientific Review Administrator, 6701 Rockledge Drive, Room 6152, Bethesda MD 20892, (301) 435-1037.

Name of SEP: Biological and Physiological Sciences.

Date: August 21, 1995.

Time: 1 p.m.

Place: NIH, Rockledge II, Room 6152, Telephone Conference.

Contact Person: Dr. Jerry Roberts, Scientific Review Administrator, 6701 Rockledge Drive, Room 6152, Bethesda MD 20892, (301) 435-1037.

Name of SEP: Biological and Physiological Sciences.

Date: August 23, 1995.

Time: 1 p.m.

Place: NIH, Rockledge II, Room 6152, Telephone Conference.

Contact Person: Dr. Jerry Roberts, Scientific Review Administrator, 6701 Rockledge Drive, Room 6152, Bethesda MD 20892, (301) 435-1037.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 2, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-19416 Filed 8-4-95; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Novel Neutrophil Chemotactic Factor, Cloned cDNA and Monoclonal Antibodies Thereto

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in a U.S. Patent Application 07/169,033 and corresponding foreign patent applications entitled, "Novel Neutrophil Chemotactic Factor, Cloned cDNA and Monoclonal Antibodies Thereto" to Chugai Pharmaceutical Company, Limited of Tokyo, Japan. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Activated monocytes/macrophages produce various mediators that cause inflammation. Among them are chemotactic factors which cause white blood cells to migrate into inflammatory sites where factors are released. Neutrophils, the dominant leukocytes attracted by the chemotactic factors play a critical role in inflammatory reactions. Rheumatoid arthritis, idiopathic pulmonary fibrosis and pathological inflammatory changes in a variety of other diseases are believed to be caused by neutrophils and/or their products. The present invention covers neutrophil chemotactic factor (interleukin-8, IL-8), a molecular clone containing the complete coding sequence for IL-8 and monoclonal antibodies to IL-8.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Raphe Kantor, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804. Telephone: (301) 496-7735 ext. 247; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in any field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Only written comments and/or applications for a license which are received by NIH on or

before October 6, 1995, will be considered. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 21, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95-19417 Filed 8-4-95; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

[Docket No. FR-3855-N-04]

NOFA for the John Heinz Neighborhood Development Program (NDP); Announcement of Funding Awards—FY 1995

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Announcement of competition winners.

SUMMARY: In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this announcement notifies the public of funding decisions made by the Department in a competition for funding under the NOFA for the John Heinz Neighborhood Development Program (NDP) for fiscal year 1995. The announcement contains the names and addresses of the competition winners and the amount of the awards.

FOR FURTHER INFORMATION CONTACT: Gene Hix, Office of Community Planning and Development, Department of Housing and Urban Development, 451 Seventh Street, SW, Room 7220, Washington, DC 20410. Telephone Number (202) 708-2186; TDD Number: (202) 708-2565. (These are not toll-free numbers.)

SUPPLEMENTARY INFORMATION: On February 24, 1995, HUD published a NOFA for the John Heinz Neighborhood Development Program (60 FR 10438). On June 26, 1995 an amendment was published in the **Federal Register** (60 FR 32557). The June 26, 1995 NOFA announced the availability of \$4.8 to \$4.95 million in funding for eligible neighborhood development organizations. The NOFA stated that the purpose of the program is to support